After the company reported it has hired Allergan‘s (NYSE: AGN) former executive chairman as its new president and CEO, investors sent shares in Impax Laboratories (NASDAQ: IPXL) surging 37.3% today.
Impax Labs’ shareholders have suffered significantly since 2015, but optimism was rekindled today by the announcement that industry veteran Paul M. Bisaro is the company’s new president and CEO.
IMAGE SOURCE: GETTY IMAGES.